Tetra Pharm Technologies advances CB1 antagonist, TPT0701, for appetite suppression into preclinical testing
/PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS),...